arsenic has been researched along with Leukocytosis in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 13 (54.17) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradley, TP; Budman, DR; Kritharis, A | 1 |
| Liu, Z; Sun, G; Wang, F; Wang, H; Wang, Y; Xi, S; Xu, Y; Yang, Y; Zheng, Q; Zheng, Y | 1 |
| Grimwade, D; Hills, RK; Jovanovic, JV | 1 |
| Anderlini, P; Borthakur, G; Brandt, M; Cortes, J; Daver, N; Dinardo, C; Ferrajoli, A; Garcia-Manero, G; Hosing, C; Kadia, T; Kantarjian, H; Marcucci, G; O'Brien, S; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Verstovsek, S | 1 |
| Gnadler, M; Hecht, A; Lengfelder, E; Mezger, J | 1 |
| Grimwade, D; Guidez, F; Mistry, AR; Solomon, E | 1 |
| Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A | 1 |
| Meng, R; Yang, BF; Zhou, J | 2 |
| Aghdami, N; Alimoghaddam, K; Bahar, B; Baybordi, E; Ghaffari, SH; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Khodabadeh, A; Mortazavi, Y; Mossavi, A; Rostami, S; Totonchi, M | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M; Rostami, S; Sanaat, Z; Shariftabrizi, A; Tavangar, M; Tavangar, SM | 1 |
| Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J | 1 |
| Hou, KZ; Jin, B; Liu, YP; Yu, P | 1 |
| Bi, KH; Jiang, GS | 1 |
| Levy, M; McLean, TW; Powell, BL; Wofford, MM | 1 |
| Kwong, YL; Todd, D | 1 |
| Harada, M; Kibata, M; Ohno, R; Omoto, E; Shudo, K; Takahashi, K; Takeuchi, M; Ueda, R; Yano, T | 1 |
| Cao, Q; Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Gu, BW; Gu, FY; Hu, J; Li, JM; Li, XS; Liu, JX; Niu, C; Ren, MY; Shen, ZX; Su, XY; Sun, HP; Wang, ZY; Waxman, S; Wu, W; Xiong, SM; Yan, H; Yang, RR; Yu, T; Yuan, MM; Zeng, XY; Zhang, FQ; Zhang, TD; Zhou, L | 1 |
| Camacho, LH; Chanel, S; Ellison, R; Heller, G; Ho, R; Scheinberg, DA; Soignet, SL; Warrell, RP | 1 |
| Warrell, RP | 1 |
| Miller, KB; Relias, V; Roberts, TF; Schenkein, D; Sprague, K | 1 |
| Calleja, E; Coutré, S; Dahlberg, S; Douer, D; Ellison, R; Frankel, SR; Kalaycio, M; Kantarjian, H; Scheinberg, DA; Sievers, EL; Soignet, SL; Steinherz, P; Stone, RM; Tallman, MS; Warrell, RP | 1 |
| Hu, J; Jin, J; Lo-Coco, F; Zhu, HH | 1 |
7 review(s) available for arsenic and Leukocytosis
| Article | Year |
|---|---|
The evolving use of arsenic in pharmacotherapy of malignant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome | 2013 |
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Differentiation; Clinical Trials as Topic; Disease Management; Drug Monitoring; Drug Resistance, Neoplasm; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Real-Time Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Tretinoin | 2014 |
Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dyspnea; Fever; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Models, Biological; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Treatment Outcome; Tretinoin | 2010 |
Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytokines; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Tretinoin | 2006 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin | 1999 |
The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Chemical and Drug Induced Liver Injury; China; Diarrhea; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis | 2019 |
8 trial(s) available for arsenic and Leukocytosis
| Article | Year |
|---|---|
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cause of Death; Child; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome | 2002 |
Comparing two arsenic trioxide administration methods in APL therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2004 |
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neovascularization, Pathologic; Oxides; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2006 |
Effects of arsenic trioxide administration styles on leukocytosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2006 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Translocation, Genetic | 1999 |
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Nervous System Diseases; Oxides; Pilot Projects; Platelet Count; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Syndrome | 2001 |
10 other study(ies) available for arsenic and Leukocytosis
| Article | Year |
|---|---|
Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Liver; Liver Function Tests; Male; Methylation; Middle Aged; Oxides; Sex Factors; Young Adult | 2013 |
[Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Dyspnea; Female; Fever; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Leukocytosis; Lung Diseases; Oxides; Risk Factors; Severity of Illness Index; Syndrome; Treatment Outcome; Tretinoin | 2017 |
Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Topics: Antineoplastic Agents; Arsenicals; Clinical Trials as Topic; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2004 |
Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cerebral Hemorrhage; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2005 |
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Treatment Outcome | 2006 |
Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Female; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Syndrome | 2006 |
Hyperleukocytosis from arsenic trioxide.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Oxides; Recurrence | 2008 |
Delicious poison: arsenic trioxide for the treatment of leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Differentiation; Fatal Outcome; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Oxides; Splenomegaly | 1997 |
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Pleural Effusion; Syndrome; Tretinoin | 2000 |
Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Infarction; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Recurrence; Remission Induction | 2000 |